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The purpose of this study was to investigate the efficacy of four different Japanese and Chinese
herbal prescriptions, Ren-Shen-Yang-Rong-Tang (Ninjin’yoeito, NYT), Chai-Hu-Gui-Zhi-
Gan-Jiang-Tang (Saikokeishikankyoto, SKKT), Si-Jun-Zi-Tang (Shikunshito, SKT) and
Si-Wu-Tang (Shimotsuto, SMT), which are traditionally used for anemia and fatigue, against
hematotoxicity in mice treated with 5-fluorouracil (5-FU). NYT 1–100mgkg
–1day
–1 injected
orally for 7 consecutive days before and after 5-FU injection significantly suppressed reductions
in red blood cell, white blood cell and platelet counts in peripheral blood, and accelerated
their recovery. Administration of SKKT also produced a slight but significant improvement in
5-FU-induced erythrocytopenia, whereas SMT and SKT could not prevent anemia. Oral
injection of NYT also inhibited 5-FU-induced decreases in peripheral reticulocyte and bone
marrow cell counts on day 10, and markedly hastened their recovery on day 20, in a dose-
dependent manner. Erythroid progenitor colonies, such as colony forming units-erythroid and
burst forming units-erythroid, formed by marrow cells from mice treated with 5-FU were
significantly increased by oral administration of NYT. These findings suggest that NYT has
the potential to protect against hematotoxicity, and also has hematopoietic activity, through
stimulation of immature erythroid progenitor cell differentiation.
Keywords: anemia – erythroid progenitor cells – 5-fluorouracil – Kampo medicines –
Ninjin’yoeito
Introduction
Severe anemia that is resistant to medical treatment is
often observed in patients with malignancies who are
undergoing chemotherapy, and pathogenesis of this
anemia is multifactorial (1). A low level of circulating
hematopoietic growth factor such as erythropoietin
(EPO), shortened survival time of circulating red blood
cells (RBCs), and a decrease in the number of immature
erythroid cells in bone marrow, probably due to
chemotherapy or chronic inflammation, have been
demonstrated as causes of anemia (2–5). To cope with
chronic anemia, blood transfusion, as well as EPO, have
been used clinically in various situations. Clinical trials of
EPO in patients undergoing cancer chemotherapy have
shown prevention of the development of anemia,
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Clibon et al. (7) have reported that EPO cannot
sufficiently overcome the reduced hematopoiesis induced
by inflammatory cytokine tumor necrosis factor (TNF)-a.
Besides hematopoietic growth factors and transfusion,
Japanese herbal medicines, such as Juzen-taiho-to, have
been used clinically to ameliorate the erythrocytopenia,
fatigue or anorexia of patients who are undergoing
cancer chemotherapy (8,9). In one clinical trial, Juzen-
taiho-to has been reported to enhance peripheral blood
counts in cancer patients receiving radiation therapy (8),
and the active constituents have been identified as oleic
and linoleic acids (9). Recently, an anti-cancer polysac-
charide, lentinan, has been shown to stimulate prolifera-
tion of immature erythroid progenitors, burst forming
units-erythroid (BFU-E), and to improve 5-fluorouracil
(5-FU)-induced reduction of the number of BFU-E in
mice (10). We have also reported that hot-water extracts
from Angelica acutiloba Kitagawa, which is used as
herbal medicine for postmenstrual blood loss and EPO-
resistant anemia in chronic renal failure, and its main
active polysaccharide constituent increase peripheral
RBC and reticulocyte counts, as well as BFU-E mix
and colony forming unit-erythroids (CFU-E) in cultured
marrow cells from mice with 5-FU-induced anemia, and
these mechanisms are, in part, due to inhibition of
inflammatory cytokine production without EPO expres-
sion (11). These results indicate that herbal medicines and
plant metabolites that stimulate the proliferation of
erythroid progenitors, and that have the potential to
recover erythrocytopenia in animal models of anemia,
may be useful for ameliorating anemia in clinical trials.
In this experiment, we chose four different kinds of
Chinese and Japanese herbal medicines: Ren-Shen-Yang-
Rong-Tang (‘Ninjin’yoeito’ in Japanese, NYT), Chai-Hu-
Gui-Zhi-Gan-Jiang-Tang (Saikokeishikankyoto, SKKT),
Si-Jun-Zi-Tang (Shikunshito, SKT) and Si-Wu-Tang
(Shimotsuto, SMT), which are used clinically for post-
menstrual blood loss and EPO-resistant anemia, and
investigated whether their crude extracts recovered
anemia induced by 5-FU in mice. 5-FU exerts its
cytotoxic effect mainly by inhibiting thymidylate synthase
activity, and this agent has often been used in
chemotherapeutic combinations for malignancy. Using a
well-established experimental model of 5-FU-induced
anemia (10–13), we attempted to compare the therapeutic
efficacy of NYT, SMT, SKT and SKKT, and then
investigated the pharmacological mechanisms of the
effective extracts leading to erythropoiesis.
Methods
Preparation of Kampo Medicines and Hot-Water Extracts
Chopped crude drugs, which were standardized by the
Japanese Pharmacopoeia (JP) XV, were purchased from
Nakai-kohshindo (Kobe, Japan). Four different Kampo
formulas were prepared according to prescriptions for
a 1-day dose (14), and are described later (see also
Table 1). Each prescription (1-day dose) was decocted in
a beaker with 600ml water by boiling for 30min over an
electric heater (600W), and filtered through absorbent
cotton, followed by concentration in vacuo, and freeze-
drying. The yields for individual extracts are described
subsequently. NYT (yield, 8.04g): Rehmannia root
(Rehmannia glutinosa, from China) 4.0g, Japanese
Angelica root (Angelica acutiloba, from Japan) 4.0g,
Atractylodes rhizome (Atractylodes ovata, from China)
4.0g, Poria sclerotium (Poria cocos, from China) 4.0g,
Cinnamon bark (Cinnamomum cassia, from China) 2.5g,
Peony root (Paeonia lactiflora, from Japan) 2.0g,
Polygala root (Polygala tenuifolia, from China) 2.0g,
Citrus unshiu peel (Citrus unshiu, from Japan) 2.0g,
Astragalus root (Astragalus membranaceus, from China)
2.0g, Ginseng (Panax ginseng, from China) 3.0g,
Glycyrrhiza (Glycyrrhiza uralensis,o rGlycyrrhiza
glabra, from China) 1.0g, Schisandra fruit (Schisandra
chinensis, from China) 1.0g. SKKT (yield, 3.50g):
Bupleurum root (Bupleurum falcatum, from China)
6.0g, Cinnamon bark (Cinnamomum cassia, from
China) 3.0g, Trichosanthes root (Trichosanthes kirilowii,
from China) 3.0g, Scutellaria root (Scutellaria baicalensis,
from China) 3.0g, Oyster Shell (Ostrea gigas, from
Japan) 3.0g, processed ginger (steamed rhizome
of Zingiber officinale, from China) 1.0g, Glycyrrhiza
(G. uralensis,o rG. glabra, from China) 2.0g. SKT (yield,
4.54g): Ginseng (root of Panax ginseng, from China)
4.0g, Atractylodes rhizome (Atractylodes ovata, from
China) 4.0g, Poria sclerotium (Poria cocos, from China)
4.0g, Ginger (rhizome of Zingiber officinale, from China)
1.0g, Jujube (fruit of Zizyphus jujuba, from China) 2.0g,
Glycyrrhiza (root of G. uralensis,o rG. glabra, from
China) 2.0g. SMT (yield, 7.11g): Japanese Angelica root
(Angelica acutiloba, from Japan) 4.0g, Cnidium Rhizome
(Cnidium officinale, from Japan) 4.0g, Peony root
(Paeonia lactiflora, from Japan) 4.0g, Rehmannia root
(Rehmannia glutinosa, from China) 4.0g.
Analysis of Kampo Extracts by Photodiode Array
(PDA)–High Performance Liquid Chromatography
(HPLC)
HPLC analysis of the ingredients of NYT extracts was
performed using a previously described method (15), with
minor modifications. In brief, lyophilized NYT extracts
(1.0g) were individually extracted with 100ml methanol
by ultrasonication for 30min. Supernatants were
removed by centrifugation (450g) and filtrated through
a membrane filter (pore size, 0.45 mm). Then, the filtrate
was analyzed by HPLC (Hitachi, Tokyo, Japan)
equipped with L-7100 pumps, D-7000 interface, L-7455
PDA detector, L-7200 auto sampler, L-7300 column
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particle size; GL Sciences, Tokyo, Japan). The solvents
used in this analysis were 0.05% (w/w) trifluoroacetic
acid and 100% acetonitrile. For detecting ingredients of
crude extracts by HPLC, an initial solvent (100%
trifluoroacetic acid) was applied for 5min, and then
changed to 100% acetonitrile in a linear gradient manner
within 80min (flow rate, 1.0ml min
–1, column tempera-
ture 40 C). Effluents were collected and detected by UV
at 200–400nm. Peak assignment was analyzed using
system software, D-7000 HSM (Hitachi). Figure 1 shows
the results of 3D-HPLC of NYT.
Mice
The animals were treated according to the ‘Guiding
Principles for the Care and Use of Animals in the Field’
of The Physiological Society of Japan, and the present
experiment was approved by the Institute for
Experimental Animals, Kanazawa University Advanced
Science Research Center, Japan. Female C57BL/6J mice,
8–9 weeks of age, were purchased from Japan SLC
(Shizuoka, Japan). Mice were housed in groups of eight
in plastic cages with a 12/12h light/dark cycle and
free access to water and mouse chow ad libitum.A n
adaptation period of at least 1 week for these conditions
was allowed before the experiment.
Experimental Protocol
5-FU (Hoffman La Roche–Kyowa, Tokyo, Japan) at
150mgkg
–1 (0.01mlg
–1 body weight) was dissolved in
saline and injected intravenously into the tail vein
(on day 0) (11). All samples dissolved in distilled water
were injected orally at 1–100mgkg
-1day
–1 once a day for
7 consecutive days (days –3 to þ3). For the second
Table 1. Ingredients of four Kampo formulas used clinically for anemia
Kampo prescription Plant name Part used Composition (g)
NYT Angelica acutiloba Kitagawa Root 4.0
Ren-Shen-Yang-Rong-Tang Astragalus membranaceus Fisch. Root 4.0
Atractylodes ovata DC. Rhizome 2.0
Cinnamomum cassia Blume.* Bark 2.5
Citrus unshiu Marc. Peel 2.0
Glycyrrhiza uralensis Fisch.* Root 1.0
Paeonia lactiflora Pall. Root 2.0
Panax ginseng C.A. Meyer Root 3.0
Polygala tenuifolia Willd. Root 2.0
Poria cocos (FR.) Wolf. Sclerotium 4.0
Rehmannia glutinosa Lib. var. purpurea Makino Root 4.0
Schisandra chinensis (Turcz.) Baill Fruit 1.0
SKKT Bupleurum falcatum L. Root 6.0
Chai-Hu-Gui-Zhi-Gan-Jiang- Cinnamomum cassia Blume.* Bark 3.0
Tang Glycyrrhiza uralensis Fisch.* Root 2.0
Ostrea gigas Shell 3.0
Scutellaria baicalensis Georgi. Root 3.0
Trichosanthes kirilowii var. japonica Root 3.0
Zingiber officinale Rocs. Steamed rhizome 1.0
SKT Atractylodes ovata DC. Rhizome 4.0
Si-Jun-Zi-Tang Glycyrrhiza uralensis Fisch. Root 2.0
Panax ginseng C.A. Meyer Root 4.0
Poria cocos (FR.) Wolf. Sclerotium 4.0
Zingiber officinale Rocs. Rhizome 1.0
Zizyphus jujube Miller var. inermis Rehder Fruit 2.0
SMT Angelica acutiloba Kitagawa Root 4.0
Si-Wu-Tang Cnidium officinale Makino Rhizome 4.0
Paeonia lactiflora Pall. Root 4.0
Rehmannia glutinosa Lib. var. purpurea Makino Root 4.0
Composition of crude drug in each prescription indicated as 1-day dosage. Asterisks indicate similarity of ingredients between NYT and SKKT.
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injected with 50ng murine recombinant interleukin-3
[IL-3; dissolved in pyrogen-free PBS containing 0.5%
bovine serum albumin (BSA); Genzyme, Boston, MA,
USA], simultaneously with 5 U murine recombinant
EPO (mrEPO; dissolved in pyrogen-free PBS containing
0.5% BSA; Roche, Mannheim, Germany). The disease
control group was treated withvehicle.
Hematological Analysis
Peripheral blood samples were collected on days 0, 5,
10,15 and 20 by the ocular sinus sampling method with
an EDTA-coated capillary tube. White blood cells
(WBCs), red blood cells (RBCs), platelets and erythro-
cytic parameters, including hemoglobin (Hb) concentra-
tion and hematocrit (Ht), were counted using an
automatic hemocytometer (Horiba, MICROS abc,
LC-152, Kyoto, Japan) (11,16). Peripheral reticulocytes
were enumerated according to a method described by
Brecher and Schneiderman (17). That is, freshly prepared
methylene blue solution was mixed with an equal volume
of peripheral blood and incubated for 15min at room
temperature. Then, blood smears were prepared on glass
slides using a cytocentrifuge (Hitachi, Ibaraki, Japan)
and stained with Wright solution (Muto Pure Chemicals,
Tokyo, Japan). Microscopic observation was performed
using an ocular micrometer disk, as described by Brecher
and Schneiderman (17).
Marrow Cell Preparation and CFU Assay
Bone marrow was obtained from tibiae and femurs, as
described previously (16). Briefly, a cell suspension
collected by aspirating the bone with a syringe filled
with PBS was washed twice with the same buffer.
Marrow cells were counted individually by a hemocyto-
meter, and stored in plastic tubes, on ice, before CFU
assays were performed. The marrow cell suspension was
then washed twice with a-MEM (Invitrogen, Carlsbad,
CA, USA) with 10% fetal bovine serum (FBS), and
resuspended in the same medium. CFU-E and BFU-E in
femoral bone marrow were analyzed using
methylcellulose-based colony assays (11,12,18). Cell
suspensions were gently mixed with 0.8% methyl cellulose
in a-MEM medium containing 30% FBS, 1% BSA,
200mM hemin and 100mM 2-mercapthoethanol. For
developing CFU-E (late erythroid progenitors),
1 10
5cellsml
–1 were plated in 35mm Petri dishes, and
stimulated with 2UmrEPOml
–1 for 2 days. For devel-
oping BFU-E mix (myeloid-mixed early erythroid popu-
lation), the marrow cell suspensions (2 10
5cellsml
–1)
were plated in the same dishes, and stimulated with
2UmrEPOml
–1 and 5ngIL-3ml
–1 for 9 days. All dishes
were incubated at 37 C in a humidified 5% CO2
incubator. After 2 days (for CFU-E) or 9 days (for
BFU-E mix), the methylcellulose discs were transferred to
glass slides and fixed with glutaraldehyde solution (2% v/
v in PBS). Both colonies (BFU-E mix and CFU-E) were
enumerated under a microscope. Only colonies consisting
of at least 10 cells were counted.
Statistics
Results are expressed as the mean SE of at least three
independent experiments. Statistical significance was
determined by Dunnett’s multiple test after one-way
analysis of variance (ANOVA), by comparison with
a physiologically normal or a disease control group, and
P50.05 was considered significant.
Results
PDA–HPLC Profile of NYT
As depicted in Fig. 1, PDA–HPLC analysis revealed that
broad peaks of chemical constituents from NYT
appeared at various retention times. UV and LC-MS/
MS analyses of reference compounds indicated the
presence of the following known constituents of NYT:
paeoniflorin (peak 1) from Peony root, liquiritin (peak 2),
isoliquiritin apioside (peak 5), isoliquiritin (peak 6),
liquiritigenin (peak 7) and glycyrrhizin (peak 8) from
Glycyrrhiza, narirutun (peak 3) and hesperidin (peak 4)
from Citrus Unshiu peel, cinnamaldehyde (peak 9) from
Cinnamon bark, and schizandrin (peak 10) from
Schisandra fruit.
Oral Administration of NYT and SKKT Improved
Erythrocytopenia in Mice Treated with 5-FU
We first examined the kinetics of peripheral RBCs after a
higher dose of 5-FU. The experimental protocol is shown
in Fig. 2. Peripheral anemia appeared 10 days after
intravenous injection of 5-FU 150mgkg
–1. The recovery
Figure 1. PDA–HPLC profile of NYT extracts. Major peaks identified
are: 1, paeoniflorin; 2, liquiritin; 3, narirutun; 4, hesperidin; 5,
isoliquiritin apioside; 6, isoliquiritin; 7, liquiritigenin; 8, glycyrrhizin;
9, cinnamaldehyde; 10, schizandrin.
250 Oral administration of Ren-Shen-Yang-Rong-Tang ‘Ninjin’Yoeito’of RBCs, Ht and Hb began on day 10 and was almost
completed by day 20 (Fig. 2). Oral NYT 100mgkg
–1day
–1
for 7 consecutive days significantly improved erythrocyto-
penia (Fig. 2A) and the reduction in Ht and Hb levels on
days 10 and 20, whereas SKT and SMT did not improve
anemia in mice treated with 5-FU (Fig. 2B and C). SKKT
100mgkg
–1day
–1 produced a slight improvement in
anemia, although to a lesser extent than NYT treatment.
Since IL-3 is known to stimulate differentiation of
hematopoietic progenitor cells (19,20), and mrIL-3 has
beenusedasapositivecontrolinpreviousworks(16,18),we
tested the efficacy of mrIL-3 (50ng per mouse)
in combination with mrEPO (5U per mouse) on
5-FU-induced anemia. On day 10, the 5-FU-induced
anemia decreases in RBCs, Ht; and Hb were strongly
suppressed by subcutaneous injection of mrIL-3/mrEPO
for 7 consecutive days (Fig. 2). Furthermore, mrIL-3/
mrEPO hastened recovery of these erythrocyte parameters
on day 20 (Fig. 2). Peripheral RBCs, Ht, and Hb levels in
physiological control mice were 9.3 0.2 ( 10
6cellsml
–1),
41.5 0.9%, and 11.6 0.2gdl
–1, respectively. None of
the treatments showed any toxic effects in normal mice, as
demonstrated by the fact that body and liver weights did
not change (data not shown), and the activity of plasma
hepatic marker enzyme, alanine aminotransferase (ALT,
EC 2.6.1.2), was not elevated (12.1 1.0Ul
–1, vehicle once
a day for 7 consecutive days, n¼3; 18.0 1.5Ul
–1,
100mgkg
–1day
–1 NYT once a day for 7 days, n¼5;
19.9 2.0Ul
–1, 100mgkg
–1day
–1 SKKT once a day for 7
days, 16.6 0.2Ul
–1,100mgkg
–1day
–1SKTonce adayfor
7 days, n¼5; 15.1 1.1Ul
–1, 100mgkg
–1day
–1 SMT once
a day for 7 days, n¼5).
NYT Suppressed Leukocytopenia and Thrombocytopenia
as Well as Reduction of Peripheral Reticulocyte
Counts Induced by 5-FU
Since oral NYT was more effective than the other
Kampo extracts for improving erythrocytopenia, we
next examined the dose-response of the protective activity
of NYT against hematotoxicity in anemic mice. 5-FU
administered to normal mice reduced not only the
Figure 2. Time course kinetics of RBCs, Hb, and Ht in peripheral blood after 5-FU injection. An experimental protocol is also shown. 5-FU
(150mgkg
–1) was injected intravenously into mice on day 0. Peripheral blood samples were collected at the indicated times, and then erythrocyte
parameters were measured using an automatic hemocytometer. All tested Kampo samples were orally administered to mice once daily from days –3
to þ3 after 5-FU treatment. One group of 5-FU-treated mice was treated subcutaneously with mrIL-3 (50ng per mouse) and mrEPO (5U per
mouse). Values are presented as the mean SE (n¼8–11). *P50.05 compared to 5-FU-treated mice.
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thrombocytopenia by 50.0 and 62.7% on day 10,
respectively (Table 2). These reductions were recovered
on day 20, and rebound reactions were observed in
the case of platelet and leukocyte counts at this time
(Table 2). NYT suppressed 5-FU-induced anemia and
accelerated the recovery of erythrocytopenia at
doses of 1–100mgkg
–1day
–1 in a dose-dependent
manner (Table 2). Furthermore, oral NYT also
suppressed leukocytopenia in a dose-dependent manner,
but did not affect thrombocytopenia at any dose (Table
2). Subcutaneous injection of mrIL-3/mrEPO, as a
positive control, markedly improved anemia and throm-
bocytopenia induced by 5-FU.
Because peripheral reticulocyte count reflects erythro-
poiesis (21), we enumerated peripheral reticulocytes and
femoral marrow cells in mice treated with NYT after
5-FU injection. The numbers of myelocytes in bone
marrow and reticulocytes in peripheral blood were
dramatically reduced 10 days after 5-FU injection (Fig.
3A and C). On day 20, the number of marrow cell was
still reduced (Fig. 3B), whereas reticulocyte count had
recovered (Fig. 3D). Bone marrow seems to be more
sensitive than peripheral reticulocytes to 5-FU (Fig. 3).
NYT 100mgkg
–1day
–1 significantly protected against the
5-FU-induced cytotoxicity of reticulocytes and myelo-
cytes, and hastened recovery of the number of these
hematopoietic cells (Fig. 3B and D). These effects of
NYT were more pronounced on day 20 than on day 10.
Protective effects against myelotoxicity and hematotoxi-
city were also observed in mice treated with subcutaneous
mrIL-3 and mrEPO (Fig. 3).
NYT-Stimulated Immature Erythroid Colony-Formation
in Cultured Marrow Cells
Since NYT showed the greatest anti-anemic activity, the
effect of oral NYT on the expression of immature
erythroid progenitor cells obtained from anemic mice
was examined. Table 3 shows the results of the colony-
forming assay for IL-3/EPO-induced BFU-E mix and
EPO-induced CFU-E. The developing colonies of BFU-E
mix and CFU-E in cultured bone marrow cells from
normal mice were  3200 and 44000 per femur, respec-
tively. Intravenous 5-FU dramatically reduced their
formation by up to 90% on day 5, and only CFU-E
formation was completely recovered on day 10 (Table 3).
The reduced BFU-E mix was recovered by up to 60% on
day 15. NYT 1–100mgkg
–1day
–1 increased development
of both colonies in a dose-dependent manner, and
recovery of BFU-E mix and CFU-E formation was
greater in the NYT-treated mice compared with that
in the disease control and normal groups (Table 3).
A tendency for their colonies to increase was observed in
mice treated with NYT, even at a low dose
(1mgkg
–1day
–1, Table 3). Moreover, subcutaneous
Table 2. Effects of NYT and IL-3 plus EPO on WBC, RBC and platelet counts and hematologic parameters in peripheral blood after 5-FU
administration
Day Treatment Dose WBC RBC Ht Hb PLT
(mgkg
–1 per day) ( 10
3ml
 1)(  10
6ml
–1) (%) (gdl
–1)(  10
3ml
–1)
0 Normal – 3.8 0.1 9.7 0.3 44.2 0.5 14.0 0.1 338 6
Control – 3.3 0.2 9.5 0.2 43.8 1.0 14.9 0.3 407 6
NYT 1 4.1 0.3 9.9 0.1 47.1 0.2 15.5 0.1 467 14
NYT 10 5.3 0.1* 10.2 0.2 47.1 0.9 15.7 0.2 520 12
NYT 100 5.2 0.1 10.1 0.1 46.7 0.4 15.3 0.1 432 15
IL-3/EPO 50ngþ5U 4.8 0.3* 10.2 1.3 48.7 1.0* 15.0 0.7 555 12*
10 Control – 1.9 0.2
# 6.0 0.3
# 27.3 1.2
# 9.5 0.1
# 126 9
#
NYT 1 2.4 0.2 6.9 0.2* 30.3 0.3* 10.6 0.3* 109 1
NYT 10 4.2 0.9* 7.6 0.3* 34.0 1.1* 11.5 0.4* 137 8*
NYT 100 4.2 0.4* 8.3 0.1* 40.4 0.1* 12.6 0.2* 146 8*
IL-3/EPO 50ngþ5U 2.8 0.4
# 8.1 0.2* 41.1 0.2* 13.0 0.1* 163 2*
20 Control – 14.1 1.7
# 7.3 0.2 41.4 0.7 13.2 0.5 1432 165
#
NYT 1 12.9 1.2* 8.8 0.1* 40.0 0.7 12.9 0.1 1226 103*
NYT 10 16.9 1.5* 8.5 0.2* 40.2 1.0 13.2 0.4 1386 180
NYT 100 16.2 1.7* 9.0 0.3* 43.5 0.7 13.5 0.2 1493 188
IL-3/EPO 50ngþ5U 13.1 1.6 10.1 1.0* 48.2 0.1* 15.2 0.1* 1512 90*
Mice were injected orally with NYT or subcutaneously with IL-3 (50ng per mouse) and EPO (5U per mouse) once daily for 7 consecutive days
from 3 days before to 3 days after 5-FU injection. Peripheral blood samples were collected on days 0, 10 and 15, and hematologic parameters
were measured by hemocytometer. Data are expressed as the mean SE of three independent experiments.
#P50.05 compared to normal mice. *P50.05 compared to 5-FU-treated mice.
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markedly stimulated colony formation of BFU-E mix
and CFU-E (Table 3). Oral administration of NYT
(Table 3) and other Kampo extracts (data not shown) did
not affect marrow cell viabilities at any time points.
Although no data are shown, increased BFU-E mix and
CFU-E colony formation in mice-treated with NYT
(100mgkg
–1day
–1) or mrIL-3/EPO on day 15 (Table 3)
reverted to normal levels on day 30.
Discussion
To elucidate therapeutic evidences for anti-anemic effect
of Kampo medicine, we evaluated the therapeutic effects
of four Kampo extracts, traditionally used for anemia
and fatigue, on 5-FU-induced anemia. Fujii et al. (22),
have previously reported that intraperitoneal injection of
NYT 625mg into BALB/c mice significantly accelerates
recovery of erythrocyte count after transplantation of
bone marrow cells from syngeneic mice, and this regimen
also enhances the total number of CFU-E, BFU-E, and
CFU-macrophages in bone marrow and spleen after
lethal total body irradiation and syngeneic bone marrow
transplantation. However, it is well known that intraper-
itoneal or intravenous injection of test substances
contaminated with endotoxin interferes with experimental
results in vivo, because endotoxin is widely distributed
in natural materials, and causes non-specific immune
responses through monocyte activation (23). Indeed,
endotoxin reportedly induces hematopoietic growth
factors such as granulocyte–macrophage colony stimulat-
ing factor (GM-CSF), G-CSF and M-CSF in monocytes
(24,25). Therefore, the net efficacy of NYT in anemia is
still unknown. In order to avoid the interference of
endotoxin and evaluate the net effects of Kampo extracts
on anemia, we used endotoxin-non-responder C57BL/6J
mice and oral injection in this study.
Of the Kampo extracts tested in this experiment,
oral injection of NYT into C57BL/6J mice protected
against myelotoxicity and hastened recovery of anemia
(Fig. 2, Table 2). We found that SKKT also significantly
prevented erythrocytopenia caused by 5-FU, but its effect
was weaker than that of NYT (Fig. 2). These results
therefore strongly suggest that NYT and SKKT have net
anti-anemic activity. Furthermore, the timing of NYT
and SKKT administration with anemic patients is
Figure 3. Effect of NYT on the reduced number of bone marrow cells and reticulocytes in mice treated with 5-FU. The number of peripheral
reticulocytes and femur marrow cells were determined at 10 and 15 days after 5-FU injection. All tested Kampo samples were administered orally to
mice once daily from days –3 to þ3 after 5-FU treatment. One group of 5-FU-treated mice was treated subcutaneously with mrIL-3 (50ng per
mouse) and mrEPO (5U per mouse). Values are presented as the mean SE (n¼8–11). *P50.05 compared to 5-FU-treated mice.
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effect of SKKT is weaker than that of NYT (Fig. 2).
We have recently reported that orally administered
hot-water extract of Angelica roots (Angelica acutiloba
Kitagawa) and an extract fraction rich in polysaccharide
protect against erythrocytopenia, and significantly
improve recovery from 5-FU-induced anemia (11).
Unexpectedly, SMT, which is mainly composed of
Angelica roots (Table 1), could not ameliorate 5-FU-
induced anemia, even at a higher dose (500mgkg
–1day
–1,
data not shown), in contrast to the effect of NYT (also
composed of Angelica roots) (Fig. 2). Although it is
unclear why SMT could not prevent erythrocytopenia in
this experiment, it could be discussed that the other crude
drug in the SMT preparation affects the anti-anemic
effect of Angelica root (11). Kiyohara et al. (26) recently
reported that combined decoction of all essential herbs in
Kampo prescription is important to elicit the combina-
tion of ingredients required for expression of the specific
activity. Hence, we are now planning to investigate the
influence of combination of crude Angelica root-contain-
ing drugs on anti-anemic activity in the same model, and
to isolate further active constituents from hot-water
extracts of NYT. Indeed, Juzentaihoto (Shi-Quan-Da-
Bu-Tang in Chinese), whose active substances have been
identified as oleic and linoleic acids, is well known to
have anti-anemic activity, and to stimulate proliferation
of hematopoietic stem cells in vitro and in vivo (9).
NYT has been reported to protect against 5-FU- and
cyclophosphamide-induced leukocytopenia at a dose of
1000mgkg
–1day
–1 (for 4 consecutive days), when
co-administered with G-CSF (27). In this study, identical
results were obtained in 5-FU-treated mice treated with
oral NYT at 1–100mgkg
–1day
–1; these doses of NYT
were sufficient for recovery from 5-FU-induced leukocy-
topenia, without co-administration of any other hemato-
poietic growth factor such as GM-CSF (Table 2). Hence,
it is clear that NYT itself has the potential to induce
recovery from erythrocytopenia and leukocytopenia in
anemic mice.
5-FU has been shown not to damage hematopoietic
stem cells directly (28,29), because stem cells rapidly
begin proliferation after 5-FU chemotherapy and become
sensitive to lineage-specific hematopoietic growth factors
(30). Intravenous 5-FU caused a decrease in the RBC,
Hb and Ht levels in mice during the experimental period
(20 days), with the maximum decrease noted on day 10
(Fig. 2). Estimation of the immature erythroid cells in
peripheral blood and bone marrow demonstrated that
there was an increase in the number of those cells on days
10 and 20 (Fig. 3). Since CFU-E is less mature than
peripheral reticulocytes, the maximum recovery of
CFU-E was on day 10 (Table 2) and the recovery of
reticulocytes was on day 20 (Fig. 3D). Furthermore, as
BFU-E is known to be more immature than CFU-E,
BFU-E recovery was expected to occur earlier than that
Table 3. Effects of NYT and IL-3 plus EPO on formation of CFU-E and BFU-E colonies in cultured marrow cells from mice treated with 5-FU
Day Treatment 5-FU Dose Cell viability CFU-E BFU-E mix n
(150mgkg
–1) (mgkg
–1day
–1)( % ) (  10
3 per femur) ( 10
2 per femur)
5 Normal – – 95.7 0.6 43.6 1.0 32.0 0.6 5
Control þ – 94.8 0.1 1.6 0.3
# 0.9 0.1
# 9
NYT þ 1 93.0 0.1 2.2 0.5 2.0 0.9* 10
NYT þ 10 94.5 0.4 3.3 0.5* 9.6 1.2* 8
NYT þ 100 97.6 0.1 9.0 0.7* 11.1 0.5* 8
IL-3/EPO þ 50ngþ5U 96.6 0.3 18.6 1.9* 15.5 2.0* 8
10 Control þ – 93.7 0.8 39.0 2.1 8.0 0.4
# 7
NYT þ 1 92.2 1.0 37.9 4.0 8.2 0.1 8
NYT þ 10 96.2 0.4 45.2 1.8* 8.8 0.1 8
NYT þ 100 94.4 0.4 57.9 3.3* 10.0 0.3* 7
IL-3/EPO þ 50ngþ5U 94.9 0.6 81.9 9.7* 13.8 0.3* 7
15 Control þ – 97.4 0.2 29.2 1.1
# 20.0 1.4
# 8
NYT þ 1 97.5 1.0 32.2 3.0 31.2 0.6* 8
NYT þ 10 94.5 0.7 40.0 3.5* 36.8 0.3* 9
NYT þ 100 95.4 0.6 57.9 2.4* 51.7 2.4* 8
IL-3/EPO þ 50ngþ5U 95.1 0.1 77.1 4.7* 69.1 1.3* 8
Mice were injected orally with NYT or subcutaneously with IL-3 (50ng per mouse) and EPO (5U per mouse) for 7 consecutive days before and
after 5-FU injection. Marrow cells were collected at 5, 10 and 15 days after 5-FU injection, and cultured with 2Uml
–1 EPO with (for BFU-E mix) or
without 5ngml
–1IL-3 (for CFU-E). The developing colonies were enumerated 2 (CFU-E) or 9 (BFU-E mix) days after cultivation. Data are
expressed as the mean SE.
#P50.05 compared to normal mice. *P50.05 compared to 5-FU-treated mice.
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mix, which contains immature myeloid cells and mega-
karyocytes, was on day 15 in a CFU assay (Table 3). Our
results are in agreement with those of Rich (12), who
demonstrated erythropoiesis in mice after 5-FU injection.
We found that oral NYT increased the number of
marrow cells and reticulocytes, especially on day 20 (Fig.
3B and D). Furthermore, NYT significantly increased the
numbers of both CFU-E and BFU-E mix colonies on
days 10 and 15 (Table 3). These results suggest that NYT
stimulates early differentiation of erythroid lineage cells
in bone marrow after 5-FU toxicity, thereby promoting
hematopoiesis.
We have recently reported that the detailed mechanisms
by which hot-water extracts of Angelica roots increase
recovery of erythrocytopenia, and stimulate differentia-
tion of erythroid progenitors without promoting EPO
synthesis, may be partly due to inhibiting the secretion of
inflammatory cytokines such as TNF-a and interferon
(IFN)-g (11). Besides the therapeutic efficacy of NYT in
anemia, it has been reported that NYT suppresses
production of TNF-a (31) in cultured rabbit alveolar
macrophages, and intraperitoneal NYT in mice also
inhibits IFN-g production in splenocytes co-stimulated
with anti-CD3 monoclonal antibody (32). Although we
did not measure the expression of EPO mRNA in liver
and kidney after NYT treatment, it can be assumed that
NYT treatment promotes erythropoiesis, possibly in
part, due to inflammatory cytokine production (TNF-a
and IFN-g), the presence of which may suppress the
differentiation of erythroid progenitor cells. To clarify the
detailed anti-anemic mechanism of NYT (and SKKT),
further investigations of the effect of NYT on EPO
expression and cytokine production in 5-FU-induced
anemia are required.
In summary, the present study demonstrates that oral
NYT can ameliorate 5-FU-induced anemia and hasten
recovery of erythrocytopenia, by stimulating the expres-
sion of early erythroid progenitor cells. Therefore, NYT
(and SKKT) has therapeutic and prophylactic potential
for erythrocytopenia and leukocytopenia, especially when
caused by anti-cancer agents.
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